Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M14,964Revenue $M4,464Net Margin (%)7.5Z-Score4.4
Enterprise Value $M15,936EPS $2.0Operating Margin %10.5F-Score7
P/E(ttm))45.0Cash Flow Per Share $4.7Pre-tax Margin (%)8.7Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %-5.1Quick Ratio1.4Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %-10.3Current Ratio2.3Lower Leverage y-yY
Price/Cash Flow6.8y-y EBITDA Growth Rate %221ROA % (ttm)5.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)10.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M171ROI % (ttm)-1.9Gross Margin Increase y-yY

Gurus Latest Trades with HSP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HSPJoel Greenblatt 2014-12-31 Sold Out -0.16%$48.12 - $62.84
($56.62)
$ 87.4635%Sold Out0
HSPJohn Rogers 2014-12-31 Reduce-0.08%$48.12 - $62.84
($56.54)
$ 87.4635%Reduce -5.02%2,311,309
HSPVanguard Health Care Fund 2014-12-31 Reduce-0.05%$48.12 - $62.84
($56.54)
$ 87.4635%Reduce -4.87%7,966,970
HSPMario Gabelli 2014-12-31 Add0.03%$48.12 - $62.84
($56.51)
$ 87.4635%Add 38.25%352,370
HSPJohn Rogers 2014-09-30 Reduce-0.45%$49.59 - $56.21
($53.12)
$ 87.4639%Reduce -22.28%2,433,369
HSPJoel Greenblatt 2014-09-30 Buy 0.16%$49.59 - $56.21
($53.12)
$ 87.4639%New holding313,242
HSPMario Gabelli 2014-09-30 Add0.01%$49.59 - $56.21
($53.12)
$ 87.4639%Add 24.71%254,870
HSPJohn Rogers 2014-06-30 Reduce-0.53%$42.14 - $52.41
($47.4)
$ 87.4646%Reduce -24.15%3,130,809
HSPMario Gabelli 2014-06-30 Add0.01%$42.14 - $52.41
($47.4)
$ 87.4646%Add 32.91%204,370
HSPBrian Rogers 2014-03-31 Sold Out -0.37%$40.89 - $45
($42.84)
$ 87.4651%Sold Out0
HSPJohn Rogers 2014-03-31 Reduce-0.28%$40.89 - $45
($42.84)
$ 87.4651%Reduce -11.62%4,127,850
HSPVanguard Health Care Fund 2014-03-31 Add0.18%$40.89 - $45
($42.83)
$ 87.4651%Add 22.69%8,375,170
HSPMario Gabelli 2014-03-31 Add0.01%$40.89 - $45
($42.84)
$ 87.4651%Add 30.68%153,770
HSPJohn Rogers 2013-12-31 Add0.12%$38.53 - $42.19
($40.25)
$ 87.4654%Add 5.28%4,670,630
HSPRichard Pzena 2013-09-30 Sold Out -0.27%$38.45 - $42.03
($39.88)
$ 87.4654%Sold Out0
HSPJohn Rogers 2013-09-30 Reduce-0.23%$38.45 - $42.03
($39.88)
$ 87.4654%Reduce -7.79%4,436,305
HSPJohn Rogers 2013-06-30 Add0.34%$30.57 - $38.31
($33.81)
$ 87.4661%Add 12.97%4,811,105
HSPBrian Rogers 2013-06-30 Add0.24%$30.57 - $38.31
($33.81)
$ 87.4661%Add 135.30%2,750,000
HSPMichael Price 2013-03-31 Add0.65%$28.96 - $35.99
($32.42)
$ 87.4663%Add 61.62%400,000
HSPVanguard Health Care Fund 2013-03-31 Add0.62%$28.96 - $35.99
($32.42)
$ 87.4663%Add 242.15%6,826,070
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HSP is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


HSP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stober Matthew RSVP, Operations 2015-03-02Sell21,833$87.490.17view
Stober Matthew RSVP, Operations 2015-02-27Sell25,338$87.470.19view
Werner Thomas ESVP, Finance & CFO 2015-02-17Sell1,566$87.350.33view
Werner Thomas ESVP, Finance & CFO 2015-01-15Sell10,000$61.5642.37view
Stober Matthew RSVP, Operations 2015-01-12Sell2,000$61.841.81view
Werner Thomas ESVP, Finance & CFO 2014-12-15Sell10,000$60.8644view
Hoffman Richard JCVP, Controller & CAO 2014-12-02Sell21,850$60.3245.29view
SOKOLOV JACQUE JDirector 2014-11-28Sell7,547$60.3245.29view
Yoskowitz Marc JSVP, Strategy & Corporate Dev 2014-11-25Sell11,523$59.9346.24view
Meyers Kenneth FSVP, Chief Human Resources Ofr 2014-11-24Sell46,250$59.6646.9view

Press Releases about HSP :

    Quarterly/Annual Reports about HSP:

    News about HSP:

    Articles On GuruFocus.com
    Weekly 52-Week Highs Highlight: SIAL, GIS, TJX, HSP Mar 30 2015 
    Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
    Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
    Feeling Good With This Med Company Jan 20 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
    Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
    Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
    Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 
    Five Companies Cut - Pzena Investment Management Update Nov 12 2013 


    More From Other Websites
    Banks see talent flee amid healthcare M&A boom Apr 14 2015
    Will Pharmaceutical Sales Drive J&J (JNJ) Earnings Again? - Analyst Blog Apr 13 2015
    Hope for Greater Access for Patients to Biosimilar Medicines Apr 13 2015
    Hope for Greater Access for Patients to Biosimilar Medicines Apr 13 2015
    The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog Apr 10 2015
    Hospira Slammed with Another Warning Letter by the FDA - Analyst Blog Apr 08 2015
    Hospira hit with further FDA scrutiny after $17 billion Pfizer deal Apr 08 2015
    Hospira to Announce First-Quarter 2015 Results on April 28, 2015 Apr 07 2015
    Hospira to Announce First-Quarter 2015 Results on April 28, 2015 Apr 07 2015
    Boston Scientific Boosts Endoscopy Business, Buys Xlumena - Analyst Blog Apr 07 2015
    Hospira hit with another FDA warning letter Apr 07 2015
    Hospira gets FDA warning letter for Italian facility Apr 07 2015
    HOSPIRA INC Files SEC form 8-K, Other Events Apr 07 2015
    How Actavis and Allergan Merger May Boost Branded Business Apr 03 2015
    The Medicines Co. Settles Angiomax Patent Dispute with Sun - Analyst Blog Apr 02 2015
    These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter Apr 02 2015
    North American Brands’s Position of Strength Apr 02 2015
    3 Key Therapeutic Segments Drive Branded Revenues Apr 01 2015
    These 10 S&P 500 Stocks Were the Best Performers in the First Quarter Apr 01 2015
    U.S. Drugmakers Facing First Wave Of Biosimilars Apr 01 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK